Genor Biopharma extends merger circular despatch amid regulatory review

Genor Biopharma Holdings Limited announced a further delay in the despatch of its circular related to the proposed very substantial acquisition and connected transaction, reverse takeover, and other corporate actions. The despatch date for the circular has been extended to on or before November 30, 2025, from the previous deadline of October 31, 2025, to address comments from regulators and update information.

The company submitted its New Listing Application to the Stock Exchange on April 15, 2025. This comprehensive announcement also covers an application for a whitewash waiver, a special deal for shareholder personnel, a proposed change of company name, an increase in authorized share capital, and the adoption of a one-off share option plan.

Shareholders and potential investors are urged to exercise caution as the merger closing is contingent on fulfilling or waiving merger conditions precedent, including the grant of the whitewash waiver and approval of the New Listing Application by the Listing Committee. Failure to secure these approvals would prevent the proposed merger from proceeding.